Anaphylaxis: Still a ghost behind allergen immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 4, 2014, Pages 316-322

  Makatsori, Melina ^a,b   Calderon, Moises A ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

allergen immunotherapy; anaphylaxis; safety; subcutaneous; sublingual

Indexed keywords

ALLERGEN;

ALLERGEN IMMUNOTHERAPY; ANAPHYLAXIS; ASTHMA; CLINICAL PRACTICE; FATALITY; HUMAN; IMMUNOTHERAPY; MEDICATION ERROR; PATIENT SAFETY; POLLEN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; REVIEW; RISK FACTOR; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT RESPONSE; DESENSITIZATION; HYPERSENSITIVITY; INCIDENCE; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INCIDENCE; INJECTIONS, SUBCUTANEOUS;

EID: 84903741342     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000075     Document Type: Review

References (56)

1. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, year 3: what practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol 2013; 110:274-278.
2. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014; 7:6.
3. Kannan JA, Epstein TG. Immunotherapy safety: what have we learned from surveillance surveys? Curr Allergy Asthma Rep 2013; 13:381-388. A review of the evidence from surveillance studies for risk factors associated with SCIT reactions.
4. Lieberman P. The risk and management of anaphylaxis in the setting of immunotherapy. Am J Rhinol Allergy 2012; 26:469-474.
5. Committee on the Safety of Medicines (CSM) in Great Britain. CSM update: desensitising vaccines. Br Med J (Clin Res Ed) 1986; 293:948.
6. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-677.
7. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993; 92:6-15.
8. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129-1136.
9. Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010; 104:530-535.
10. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract 2014; 2:161-167.
11. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; 24: CD001936.
12. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; CD001186.
13. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014; 124:616-627.
14. Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 10:CD008838.
15. Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Risk stratification of systemic allergic reactions during Hymenoptera venom immunotherapy buildup phase. J Dtsch Dermatol Ges 2014; 12:244-255.
16. Cox LS, Larenas-Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021-1035.
17. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 8:CD002893.
18. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013; 309:1278-1288.
19. Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol 2013; 13:656-662.
20. Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012; 67:302-311.
21. Vovolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol Immunopathol (Madr) 2013; 41:279-281.
22. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169-175.
23. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl.):S1-S55.
24. Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99:82-86.
25. Moreno C, Cuesta-Herranz J, Fernández-Távora L, et al. Immunotherapy safety: a prospective multicentric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004; 34:527-531.
26. Iglesias-Cadarso A, Hernández-Weigand P, Reaño M, et al. A prospective safety study of allergen immunotherapy in daily clinical practice. Allergol Immunopathol (Madr) 2004; 32:278-283.
27. Calabria CW, Stolfi A, Tankersley MS. The REPEAT study: recognizing and evaluating periodic local reactions in allergen immunotherapy and associated systemic reactions. Ann Allergy Asthma Immunol 2011; 106:49-53.
28. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004; 92:225-227.
29. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004; 113:1117-1121.
30. Patel S, Rossow KL, Williams BJ, et al. Errors in allergen immunotherapy administration: a systems assessment. Ann Allergy Asthma Immunol 2013; 110:205-206.
31. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606-610.
32. Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase: a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-1054.
33. Ruëff F, Vos B, Elberink JO, et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014. doi: 10.1111/ cea.12275.
34. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101:426-430.
35. Stoevesandt J, Hain J, Stolze I, et al. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build up phase. Clin Exp Allergy 2014. doi: 10.1111/cea. 12276.
36. Liss GM, Murphy-Berendts K, Epstein T, Bernstein DI. Factors associated with severe versus mild immunotherapy-related systemic reactions: a casereferent study. J Allergy Clin Immunol 2011; 127:1298-1300.
37. Calabria CW. Accelerated immunotherapy schedules. Curr Allergy Asthma Rep 2013; 13:389-398.
38. Feng S, Xu Y, Ma R, et al. Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic rhinitis: a systematic review and metaanalysis. PLoS One 2014; 9:e86529.
39. Balaji R, Parasuramalu BG, Chandregowda BV, Gangaboraiah. Safety, tolerability and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis. Allergol Immunopathol (Madr) 2013. pii: S0301-0546(13)00046-3.
40. Mösges R, Graute V, Christ H, et al. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. Pediatr Allergy Immunol 2010; 21:1135-1138.
41. Roger A, Justicia JL, Navarro LÁ, et al. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int Arch Allergy Immunol 2011; 154:69-75.
42. Cox L, Larenas-Linnemann D, Lockey R. Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125:569-574.
43. DaVeiga SP, Liu X, Caruso K, et al. Systemic reactions associated with subcutaneous allergen immunotherapy: timing and risk assessment. Ann Allergy Asthma Immunol 2011; 106:533-537.
44. Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 2009; 123:493-498.
45. Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol 2010; 104:73-78.
46. Walker SM, Durham SR, Till SJ, et al. British Society for Allergy and Clinical Immunology. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011; 41:1177-1200.
47. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol 2005; 95:217-228.
48. Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:600-605.
49. Müller UR, Jutel M, Reimers A, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008; 122:1001-1007.
50. Brockow K, Kiehn M, Riethmüller C, et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997; 100:458-463.
51. Casale TB, Busse WW, Kline JN, et al., Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134-140.
52. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383-389.
53. Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014; 133:937.
54. Da Silva EN, Randall KL. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract 2013; 1:687-688.
55. Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Invest Allergol Clin Immunol 2008; 18:225-226.
56. Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol 2014; 10:7.